BioNTech says 'no evidence' its jabs need adapting for variants

FILE - In this Saturday, Feb. 13, 2021 file photo the logo on the BioNTech biotechnology company displayed at the building where production of the COVID-19 vaccine has started, in Marburg, Germany. German pharmaceutical company BioNTech reported a net profit of 1.13 billion euros, about 1.37 billion US dollars, in the first quarter of this year on the back of strong revenues from its coronavirus vaccine. (AP Photo/Michael Probst, file)





Your feedback is important to us!

We invite all our readers to share with us their views and comments about this article.

Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.

Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (

comments powered by Disqus



Interested in knowing more about this story?

Click here